catalyx space | $5,400,000 | (Nov 4, 2025)
Zeeg | $1,265,935 | (Nov 4, 2025)
xMEMS | $21,000,000 | (Nov 4, 2025)
Invirsa, Inc
United States
- Columbus, Ohio
- 15/06/2023
- Series B
- $7,700,000
Invirsa is developing a small molecule (INV-102) that promotes both DNA repair and the innate immune response to infection and injury. These actions lead to enhanced wound healing associated with reductions in inflammation and viral replication.
INV-102 has demonstrated unprecedented efficacy in animal models of ocular sulfur mustard gas injury. Sulfur mustard is a dangerous chemical weapon, and INV-102 is the first drug to show promise in preventing its long-term effects. There is no current FDA approved therapy for this injury.
In September of 2020, Invirsa received a $29.6M BARDA award ($14.4M plus $15.2M in milestones) to support the clinical development of INV-102 for the treatment of ocular sulfur mustard gas injury and other ocular injuries associated with DNA damage. The award covers development through Phase 3 clinical trials.
Invirsa’s initial commercial focus for INV-102 will be infectious keratoconjunctivitis as there is no treatment for the viral form of this disease which comprises 80% of all cases. INV-102 has demonstrated clear efficacy in animal models of infectious conjunctivitis.
- Industry Pharmaceutical Manufacturing
- Website https://invirsa.com/
- LinkedIn https://www.linkedin.com/company/invirsa/
Cephia AI | $4,000,000 | (Nov 4, 2025)
Ornn | $5,700,000 | (Nov 4, 2025)
octonomy | $20,000,000 | (Nov 4, 2025)
Helex | $3,500,000 | (Nov 4, 2025)
Indomo | $25,000,000 | (Nov 4, 2025)
AUI™ (Augmented Intelligence) | $20,000,000 | (Nov 4, 2025)
Popai Health | $11,000,000 | (Nov 4, 2025)
Mem0 | $24,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)